• What best describes your title?*
  • If PharmD, DOB
     - -
    2 digit month, 2 digit day, 4 digit year
  • 1. In the CORE and CORE2 Trials of olezarsen in patients with persistent hypertriglyceridemia over 500 mg/dl despite traditional therapy, olezarsen 80 mg lowered fasting triglyceride levels by:
  • 2. The number needed to treat over one year for patients with baseline triglycerides over 880 mg/cl in the CORE and CORE 2 Trials to prevent one acute pancreatitis episode was:
  • 3. Which of the following patients would have been enrolled in the VESALIUS Trial?
  • 4. In the Phase 3 Coral Reef Trial evaluating the efficacy of oral enlicitide, what wasthe average LDL reduction at 24 weeks?
  • How many patients do you currently see each month regarding dyslipidemia?
  • Learning Objectives
    Rows
  • Please provide us with feedback regarding your experience at the activity:
    Rows
  • Do you feel this activity was fair, balanced, and free of commercial bias?
  • This educational activity will result in a change in my role as a healthcare team member.
  • Based on your participation in this activity, choose the statement(s) that applies to how your role as a healthcare team member will change:

  • Attestation:

    AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.

    AcademicCME designates this enduring material for a maximum of 1.0 CNE Contact Hour, including 1.0 Pharmacotherapeutic Contact Hour (Provider #P0491).

    AcademicCME designates this continuing education activity for 1.0 CPE Contact Hour (0.10 CEUs) of Continuing Pharmacy Education Credit (UAN # JA4008190 0000-25-036-H01-P).

    Participants should claim only the credit commensurate with the extent of their participation in the activity.

  • Date
     - -
    2 digit month, 2 digit day, 4 digit year
  • Should be Empty: